Vitilgo is non-atrophic hypopigmentation of the skin. The lesions begin as macules and may become confluent. Biopsy of these lesions reveals an absence of melanocytes. Vitiligo has been associated with diabetes, hypothroidism, Addison's disease, pernicious anemia, and candidiasis. It is also a component of the Vogt-Koyanagi-Harada syndrome.

There are various treament regimens for vitiligo: (1) a trial of high-potency topical steroids, (2) natural sunlight, or (3) PUVA therapy.

In Cuba, through the 30 plus years research and commercial development efforts of Carlos Miyares Cao, M.D. and others, the pharmaceutical, Melagenina, is marketed for use in patients with vitiligo. Melagenina stimulates reproduction of melanocytes and synthesis of melanin and treatmentis exclusively offered by the Institute of Placenta-Histotherapy. In its original version (Melagenina), the drug was applied 3 times a day (every 8 hours) supported by a special UV-phototherapy. Newly developed Melagenina Plus needs to be applied only once a day. Intense Sunlight or even UV-Light should be avoided.

This medication is not available in the USA due to the Embargo against importation of Cuban biotechnology products into the USA.